Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a clinical-stage cell therapy company developing autologous chimeric antigen receptor (CAR) T-cell therapies for cancer. Its lead candidate, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 therapy being evaluated for relapsed or refractory large B-cell… From the company’s description.
Over the twelve months to Sep 30, 2026, Lyell Immunopharma, Inc. reported revenue of $0.01M, down 63.4% from a year earlier, and a net loss of $255.16M. Operations used $139.25M in cash. In fiscal 2025, it reported revenue of $0.04M, down 41.0% from fiscal 2024, and a net loss of $274.45M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lyell Immunopharma, Inc. does
In the company’s own words
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a clinical-stage cell therapy company developing autologous chimeric antigen receptor (CAR) T-cell therapies for cancer. Its lead candidate, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 therapy being evaluated for relapsed or refractory large B-cell lymphoma, including in pivotal trials for second-line and later-line treatment. Lyell also develops LYL273, a guanylyl cyclase C-targeted CAR T-cell candidate for metastatic colorectal cancer, enhanced with CD19 CAR expression and controlled cytokine release. Its research programs explore additional CAR T-cell candidates and technologies intended to support activity in solid tumors. Lyell manufactures clinical-trial cell products at its LyFE Manufacturing Center, which is designed to have capacity for more than 1,200 CAR T-cell doses annually at full staffing and capacity. The company acquired ronde-cel through its 2024 acquisition of ImmPACT Bio and licensed LYL273 in 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1806952
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lyell Immunopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lyell Immunopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lyell Immunopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lyell Immunopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lyell Immunopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”